Associated Papers
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
Silva-Oliveira RJ et al.
Cellular Oncology (dordrecht, Netherlands), 2016
In silico and experimental validation of protein-protein interactions between PknI and Rv2159c from Mycobacterium tuberculosis.
Venkatesan A et al.
Journal of Molecular Graphics & Modelling, 2015
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
King AJ et al.
Plos One, 2013
23844038 (PubMed )
Supplement: pone.0067583.s005.pdf
The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.
Yen J et al.
Genome Biology, 2013
24148783 (PubMed )
Supplement: gb-2013-14-10-r113-S1.xlsx › Table_S3
Select a paper to view details